U.S. Markets closed
  • S&P Futures

    3,974.50
    +8.75 (+0.22%)
     
  • Dow Futures

    33,852.00
    +49.00 (+0.14%)
     
  • Nasdaq Futures

    11,678.75
    +33.25 (+0.29%)
     
  • Russell 2000 Futures

    1,822.30
    +2.60 (+0.14%)
     
  • Crude Oil

    72.06
    +0.60 (+0.84%)
     
  • Gold

    1,807.40
    +5.90 (+0.33%)
     
  • Silver

    23.48
    +0.23 (+1.01%)
     
  • EUR/USD

    1.0584
    +0.0025 (+0.23%)
     
  • 10-Yr Bond

    3.4910
    +0.0830 (+2.44%)
     
  • Vix

    22.29
    -0.39 (-1.72%)
     
  • GBP/USD

    1.2276
    +0.0038 (+0.31%)
     
  • USD/JPY

    135.8980
    -0.7320 (-0.54%)
     
  • BTC-USD

    17,207.66
    +360.58 (+2.14%)
     
  • CMC Crypto 200

    405.95
    +11.26 (+2.85%)
     
  • FTSE 100

    7,472.17
    -17.02 (-0.23%)
     
  • Nikkei 225

    27,901.54
    +327.11 (+1.19%)
     

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

Abeona Therapeutics Inc.
Abeona Therapeutics Inc.

NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 8:30 a.m. ET. The Company will also participate in one-on-one investor meetings at the conference.

A live webcast of the fireside chat will be available on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 30 days. Those interested in attending the fireside chat or requesting a one-on-one meeting with Abeona are encouraged to contact their Jefferies representative.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s lead clinical program is EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com.

CONTACT: Investor and Media Contact: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com